Aurora Cannabis Invests in German Facility

TL;DR

Aurora is pouring money into its German plant to boost European production.

AI Summary

Aurora Cannabis Inc. announced on September 18, 2025, a significant investment into its German manufacturing facility. This move is part of the company's strategy to expand its production capabilities and market presence in Europe. The specific dollar amount of the investment was not disclosed in this filing.

Why It Matters

This investment signals Aurora's commitment to growing its European operations and potentially increasing its market share in the German pharmaceutical and cannabis sectors.

Risk Assessment

Risk Level: medium — Investments in international manufacturing facilities carry inherent risks related to regulatory changes, market demand, and operational execution.

Key Players & Entities

• Aurora Cannabis Inc. (company) — Registrant
• Miguel Martin (person) — Chief Executive Officer
• September 18, 2025 (date) — Filing and News Release Date
• NASDAQ | TSX: ACB (company) — Stock Ticker

FAQ

From the Filing

0001279569-25-001017.txt : 20250918 0001279569-25-001017.hdr.sgml : 20250918 20250918085401 ACCESSION NUMBER: 0001279569-25-001017 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20250918 FILED AS OF DATE: 20250918 DATE AS OF CHANGE: 20250918 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AURORA CANNABIS INC CENTRAL INDEX KEY: 0001683541 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38691 FILM NUMBER: 251321849 BUSINESS ADDRESS: STREET 1: 2207 90B STREET SW CITY: EDMONTON STATE: A0 ZIP: T6X 1V8 BUSINESS PHONE: 604-362-5207 MAIL ADDRESS: STREET 1: 409 GRANVILLE STREET STREET 2: SUITE 1700 CITY: VANCOUVER STATE: A1 ZIP: V6C 1T2 6-K 1 aurora_6k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2025 Commission File No. 001-38691 AURORA CANNABIS INC. (Translation of registrant's name into English) 2207 90B St. SW Edmonton, Alberta T6X 1V8 Canada (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F Form 20-F ☐ Form 40-F ☒ SUBMITTED HEREWITH Exhibits Description 99.1 News release dated September 18, 2025 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. AURORA CANNABIS INC. /s/ Miguel Martin Miguel Martin Chief Executive Officer Date: September 18, 2025 EX-99.1 2 ex991.htm NEWS RELEASE DATED SEPTEMBER 18, 2025 Exhibit 99.1 Aurora Announces Investment into German Manufacturing Facility NASDAQ | TSX: ACB Facility investment includes adopting the company's unmatched global manufacturing practices for superior cannabis production and quality EDMONTON, AB, Sept. 18, 2025 /CNW/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, announces an investment over five years into operational upgrades at its EU-GMP manufacturing facility in Leuna, Germany. Building on best practices proven at Aurora's Canadian facilities, these improvements will increase flower growth capacity, product quality and drive cost efficiency. "This investment marks a significant milestone in our commitment to operational excellence and long-term growth in Europe," said Alex Miller, Executive Vice President of Operations, Science and Supply Chain at Aurora. "These upgrades will strengthen our supply chain resilience, expand our domestic capabilities in EU-GMP certified manufacturing, and position us to best meet the growing demand for high-quality medical cannabis in Europe with precision and efficiency." Aurora's global manufacturing network upholds the highest manufacturing standards that will be adopted at the German facility. With the goal of maximizing cultivation volume, the upgrades include commissioning additional grow rooms, new irrigation and lighting systems in existing rooms, and transitioning to hang dry and dry trim. As one of only three licensed cultivation facilities in the country, Aurora Leuna plays a pivotal role in supplying high-quality, locally grown medical cannabis to meet the needs of Germany's expanding patient base. Aurora Leuna currently grows cultivars under the IndiMed brand, and this expansion will enable the site to grow additional cultivars available from Aurora's leading genetics library. By continuously investing in operational capabilities, Aurora is best positioned to serve international markets at the highest standards. About Aurora Cannabis Inc. Aurora is opening the world to cannabis,